| 摘要: |
| 目的:总结全球儿童炎症性肠病(PIBD)生物制剂治疗的研究现状、热点及未来发展方向,为临床实践和研究提供参考。方法:检索2000 年1 月1 日-2025 年5 月31 日Web of Science 核心合集数据库中发表的PIBD 生物制剂治疗相关文献,利用VOSviewer、CiteSpace 及R 语言Bibliometrix 包等工具,对国家、机构、作者及关键词进行可视化分析。结果:共纳入1 270 篇文献,年发文量持续增长,2022 年达到峰值(112 篇)。研究热点主要集中于英夫利昔单抗等生物制剂,治疗药物监测及个体化治疗。关键词突现与主题演变分析显示,该领域研究正从抗肿瘤坏死因子-α 制剂向精准医疗和全周期管理转变。结论:PIBD 生物制剂治疗领域的研究发展迅速,个体化和精准医疗已成为新趋势,未来研究应更加关注儿童用药的长期安全性及疗效。 |
| 关键词: 炎症性肠病 儿童 生物制剂 文献计量分析 研究趋势 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2026.07.001 |
|
| 基金项目:国家自然科学基金项目,编号82460108;中国博士后科学基金项目,编号2025M772035。 |
|
| Visualization-Based Analysis of Global Research and Trends in Biologic Therapies for Pediatric Inflammatory Bowel Disease |
| Huang Wei1, Pan Xiaona2, Kang Mei3, Han Bing3, Lyu Xiaoping3 |
| (1. The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China; 2. International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530201, China; 3. the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China) |
| Abstract: |
| Objective: To summarize the current research status, hotspots, and future development direction of biologic therapies for pediatric inflammatory bowel disease (PIBD) worldwide, and to provide references for clinical practice and research. Methods: A systematic search of the Web of Science Core Collection was conducted for literature on biologic therapies for PIBD published from Jan. 1st , 2000 to May 31st , 2025. Visualization tools, including VOSviewer, CiteSpace, and the R-based Bibliometrix package, were employed to analyze countries, institutions, authors, and keywords. Results: A total of 1,270 publications were included. The annual publication output demonstrated sustained growth, peaking at 112 articles in 2022. Key research hotspots centered on biologics such as infliximab, therapeutic drug monitoring, and individualized treatment strategies. Analysis of keyword bursts and thematic evolution indicated aparadigm shift from anti-tumor necrosis factor-α agents toward precision medicine and holistic lifecycle management. Conclusion:Research on biologic therapies for PIBD is advancing rapidly, with an increasing emphasis on individualized and precision-basedapproaches. Future studies should prioritize long-term safety profiles and sustained therapeutic efficacy in children. |
| Key words: inflammatory bowel disease children biologics bibliometric analysis research trends |
